75% of US consumers say GLP-1s are a useful tool, not a magic cure - but 61% of users admit it can feel like cheating. The stigma is fading fast
The SURMOUNT-5 clinical trial published in The New England Journal of Medicine showed that Zepbound (tirzepatide) achieved an average weight loss of 20.2% compared to 13.7% with Wegovy (semaglutide) at 72 weeks
How Retatrutide May Be Used in the Future Upon approval, Retatrutide could be applied in: Weight management programs Fatty liver protocols GLP-1 failure rescue regimens Combination peptide protocols (e.g., with MOTS-c or BPC-157) Postmenopausal metabolic restoration Should You Wait for Retatrutide or Start Something Now
Plant Biotechnol J 14(7):15891603
Gallbladder-related events, including cholelithiasis and cholecystitis, occur more frequently with GLP-1 therapy, likely related to rapid weight loss rather than direct drug effects
You start with a short online health intake covering your history, current needs, and goals